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OBJECTIVE — The goal of this study was to examine whether metabolic abnormalities are
responsible for the histological changes observed in Japanese patients with nonalcoholic fatty
liver disease (NAFLD) who have undergone serial liver biopsies.
RESEARCH DESIGN AND METHODS — In total, 39 patients had undergone consec-
utive liver biopsies. Changes in their clinical data were analyzed, and biopsy specimens were
scored histologically for stage.
RESULTS — The median follow-up time was 2.4 years (range 1.0–8.5). Liver ﬁbrosis had
improved in 12 patients (30.7%), progressed in 11 patients (28.2%), and remained unchanged
in 16 patients (41%). In a Cox proportional hazard model, decrease in A1C and use of insulin
were associated with improvement of liver ﬁbrosis independent of age, sex, and BMI. However,
A1C was more strongly associated with the improvement of liver ﬁbrosis than use of insulin
after adjustment for each other (
2; 7.97 vs. 4.58, respectively).
CONCLUSIONS — TightglycemiccontrolmaypreventhistologicalprogressioninJapanese
patients with NAFLD.
Diabetes Care 33:284–286, 2010
A
ccumulating trans-sectional evi-
dence suggests that the presence of
multiple metabolic disorders, in-
cluding obesity, diabetes, dyslipidemia,
hypertension, and ultimately metabolic
syndrome, are associated with nonalco-
holic fatty liver disease (NAFLD) (1).
However, it remains unclear which meta-
bolicabnormalitiesareresponsibleforthe
pathological progression of NAFLD, es-
pecially in Japanese patients, who gener-
ally are not severely obese compared with
Western patients.
We retrospectively compared clinical
features with the histological changes in
the livers of Japanese patients with
NAFLD who had undergone serial liver
biopsies.
RESEARCH DESIGN AND
METHODS— We recruited 195 pa-
tients with clinically suspected NAFLD
who had undergone liver biopsies at Ka-
nazawa University Hospital from 1997
through 2008. For details about the
study subjects and the exclusion crite-
ria, see supplementary Fig. 1 in the on-
line appendix, available at http://care.
diabetesjournals.org/cgi/content/full/
dc09-0148/DC1. Of 178 patients diag-
nosedhistologicallyashavingNAFLD,39
had undergone serial liver biopsies.
Data collection
Clinical information, including age,
sex, body measurements, and preva-
lence of metabolic abnormalities, was
obtainedforeachpatient.Venousblood
samples drawn for laboratory testing
before the liver biopsies were obtained.
All subjects had been administered a
75-g oral glucose tolerance test at base-
line and at follow-up.
Liver biopsies
Biopsies were obtained after a thorough
clinical evaluation and receipt of signed
informed consent from each patient. All
biopsies were analyzed twice and at sep-
arate times randomly by a single patholo-
gist who was blinded to the clinical
information and the order in which the
biopsies were obtained. The biopsied tis-
sues were scored for steatosis, stage, and
grade as described (2), according to the
standard criteria for grading and staging
of nonalcoholic steatohepatitis proposed
by Brunt et al. (3).
For additional details on subjects,
data collection methods, liver pathology,
and statistical analyses, see supplemen-
tary Methods in the online appendix.
RESULTS— The basal clinical and
biochemical data from 39 patients with
NAFLD are described in supplementary
Table1.Prevalenceoftype2diabetes,hy-
pertension, and dyslipidemia were 77,
36, and 64%, respectively. The median
follow-up period was 2.4 years (range
1.0–8.5). Medications for diabetes and
medication changes during the follow-up
period are described in supplementary
Table 2. Seventeen patients treated with
oral diabetic agents were switched to in-
sulin therapy after the initial biopsy. No
patients initiated pioglitazone during
follow-up.
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(30.7%), progressed in 11 patients
(28.2%), and remained unchanged in 16
patients(41%).AsshowninTable1,fast-
ing plasma glucose, A1C, insulin resis-
tance indicators, and prevalence of
metabolicdisorderswerenotsigniﬁcantly
different among the three liver ﬁbrosis
groups. In the Cox proportional hazard
model(supplementaryTable3),although
some of the conﬁdence intervals were
very wide because of the small sample
size, improvement of liver ﬁbrosis was
signiﬁcantly associated with changes in
A1C between the initial and ﬁnal liver bi-
opsies (A1C) (P  0.005) and use of
insulin for the treatment of diabetes (P 
0.019). Both A1C and use of insulin
were independently associated with the
improvement of liver ﬁbrosis after ad-
justed for each other. However, A1C
wasmorestronglyassociatedwiththeim-
provement of liver ﬁbrosis than use of in-
sulin (
2; 7.97 vs. 4.58, respectively;
supplementary Table 3).
CONCLUSIONS — In the present
study, we showed that a change in glyce-
mic control (A1C), but not changes in
insulinresistanceindicators,wasaninde-
pendent predictor of the progression of
liver ﬁbrosis in Japanese patients with
NAFLD.Thisistheﬁrstreportidentifying
a change in A1C as a predictor of the his-
tological course in the liver of patients
with NAFLD. Two of ﬁve previous longi-
tudinal studies have identiﬁed obesity,
higher BMI, and homeostasis model as-
sessment of insulin resistance (HOMA-
IR)aspredictorsofliverﬁbrosisprogression
in Western populations (4,5). The differ-
encebetweenthoseresultsandtheresultsof
the present study may be due in part to
differencesintheassessedseverityofobe-
sity and insulin resistance between the
populations. We previously demon-
strated that diabetes is an independent
risk factor for the progression of liver ﬁ-
brosis in hepatitis C (6) and that diabetes
accelerates the pathology of nonalcoholic
steatohepatitis in the type 2 diabetic rat
model OLETF (7).
Liver ﬁbrosis is closely associated
withtworegulatorsofﬁbrosis:transform-
ing growth factor (TGF)- (8,9) and plas-
minogen activator inhibitor type 1
(PAI-1) (8,10). High glucose levels in-
duce the expression of TGF- (11) and
PAI-1 (12). We previously reported that
the expression of TGF family member
genes,PAI-1,andgenesinvolvedinﬁbro-
genesisareupregulatedintheliversofpa-
tients with type 2 diabetes (13,14),
suggesting that a diabetic state increases
the risk for liver ﬁbrosis.
In the present study, only A1C was
associated with the progression of liver
ﬁbrosis, but not liver inﬂammation (data
not shown). We speculate that the reduc-
tion of A1C inhibits the expression of
master genes such as TGF- and PAI-1
that are involved in the regulation of ﬁ-
brogenesis, rather than genes involved in
liverinﬂammation,andtherebyimproves
liver ﬁbrosis in NAFLD.
Themajorlimitationofthisstudywas
small population size. We could not eval-
uate the changes of liver histology
according to the difference in detail char-
acteristics such as treatment of diabetes.
Lower statistical power of this study
should be consider when we evaluate the
results.
In conclusion, our study suggested
that A1C could predict liver ﬁbrosis
progression in Japanese patients with
NAFLD, and tight glycemic control may
ameliorate liver ﬁbrosis. Future large-
scale prospective studies are needed to
conﬁrm our results.
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